Cambrex invests in generic API development and manufacturing capabilities at its Milan site

12 Oct 2017

Investments include the installation of development and analytical equipment to support the development of highly potent APIs.

Cambrex has made a number of investments, in both R&D and manufacturing capabilities to support the development and production of generic APIs, at its site in Paullo, Milan, Italy.

Cambrex invests in generic API development and manufacturing capabilities at its Milan site

The investments include the installation of development and analytical equipment to support the development of highly potent APIs (HPAPIs), as well as a new 2,800-L hydrogenator and 1,500-mm diameter centrifuge, for increased flexibility and capacity within the manufacturing plant. All equipment will be installed and validated by the end of 2017.

“We have seen increased growth of activity among highly potent molecules in the past decade for use in therapeutics for cancer and other indications, and it is now becoming more appropriate in the generic API business as patents on these begin to expire,” commented Aldo Magnini, Managing Director, Cambrex Milan. “This investment is consistent with the Cambrex strategic plan to increase the company’s small molecule development and manufacturing capabilities, ensuring our facilities continue to meet the future demands of the industry.”

This investment comes after the installation of a new pilot plant at the site in 2017, and recent announcements of expansions across the Cambrex network of manufacturing sites, including the construction of a $24M, 4,500 sq. ft. HPAPI manufacturing facility at its Charles City, Iowa site, which is due to open in 2019.

Read More

Related tags

Market News

Related news

Aptar Pharma to showcase an industry first

Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Read more 
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

11 Sep 2018

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Read more 
New SGS biopharmaceutical testing capabilities in Illinois

New SGS biopharmaceutical testing capabilities in Illinois

11 Sep 2018

The new services will focus on quality control analysis and stability testing of biopharmaceuticals.

Read more 
Exciting skincare to protect against blue light emitted by phones and devices

Exciting skincare to protect against blue light emitted by phones and devices

10 Sep 2018

Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.

Read more 
24/7 life science manufacturing IT service launches

24/7 life science manufacturing IT service launches

7 Sep 2018

Faster GMP incident response and resolution times when manufacturing IT applications fail or are not running to their optimum capacity.

Read more 
Catalent signs commercial supply agreement for Aucta Pharmaceuticals' vigabatrin

Catalent signs commercial supply agreement for Aucta Pharmaceuticals' vigabatrin

6 Sep 2018

Novel dosage form employs Catalent’s proprietary stick pack dosage form.

Read more 
Sartorius and Repligen partner to introduce next-generation perfusion-enabled bioreactors

Sartorius and Repligen partner to introduce next-generation perfusion-enabled bioreactors

5 Sep 2018

Customers to benefit from simplified, scalable solutions for intensified cell culture.

Read more 
Boehringer Ingelheim to build new tablet manufacturing facility

Boehringer Ingelheim to build new tablet manufacturing facility

4 Sep 2018

Facility to manufacture innovative drugs for worldwide market launches and technologically advanced production.

Read more 
Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell wins military contract to develop regenerative medicines for the battlefield

4 Sep 2018

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

Read more 
Bio processing and manufacturing league table ranks US top and China bottom

Bio processing and manufacturing league table ranks US top and China bottom

3 Sep 2018

US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.

Read more